Full Year 2024 Financial Results Revenue from Continuing Operations was $20.2 million for 2024, an increase of 181% compared to $7.2 million in 2023.

Acutus Medical, Inc. ("Acutus" or the "Company") (OTC: AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from ...

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025Ongoing Phase 3 ...

Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene planning to initiate the confirmatory Phase 3 RESTORE-ALS tr ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; ...

PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

"For the fourth quarter 2024, SWK's core Finance Receivables segment reported an 11.6% increase in revenue to $10.3 million ...

VANCOUVER, BC / ACCESS Newswire / / Orogen Royalties Inc. (TSXV:OGN) (OTCQX:OGNRF) ("Orogen" or the "Company") reports preliminary ...

Acquired In-Process Research and Development expense: Acquired in-process research and development expense was $51.7 million for the full year ended December 31, 2024 relating to the Company’s ...

Explore the fundamentals of cash flow statements, including their structure, significance, and the insights they provide into ...